Vaxcyte, Inc. $PCVX Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 57.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 32,212 shares of the company’s stock after purchasing an additional 11,783 shares during the quarter. SG Americas Securities LLC’s holdings in Vaxcyte were worth $1,872,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada lifted its holdings in Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after buying an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Vaxcyte during the first quarter worth $219,000. Caxton Associates LLP acquired a new stake in shares of Vaxcyte in the first quarter valued at $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Vaxcyte by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after acquiring an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers boosted its holdings in Vaxcyte by 13.8% in the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after purchasing an additional 932 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Finally, Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. This trade represents a 1.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $53.00, for a total value of $530,000.00. Following the sale, the chief financial officer directly owned 104,395 shares in the company, valued at $5,532,935. This trade represents a 8.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 66,198 shares of company stock valued at $3,571,655 over the last quarter. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Trading Up 4.1%

Shares of PCVX opened at $58.39 on Friday. The firm has a market capitalization of $8.43 billion, a price-to-earnings ratio of -8.49 and a beta of 1.22. The firm’s fifty day simple moving average is $52.26 and its 200-day simple moving average is $53.38. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the business posted ($1.04) EPS. On average, analysts predict that Vaxcyte, Inc. will post -7.91 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.